Isolated extramedullary relapse of acute lymphoblastic leukaemia (ALL) with sparing of the marrow after allogeneic bone marrow transplantation (BMT) is a rare occurrence, and the mechanisms underlying the selective involvement of extramedullary sites remain undefined. These might be due to relapse in sanctuary sites where the leukaemic cells are resistant to chemotherapy, or a stronger putative graft-versus-leukaemia (GVL) effect in the marrow as compared with peripheral tissues. We report two ALL patients with repeated episodes of extramedullary relapse after BMT in whom both mechanisms might be operating. In the first patient, the marrow was in morphologic and molecular remission before isolated leukaemic relapse in the central nervous system (CNS) occurred. Subsequent secondary infiltration of leukaemic cells into the marrow was only evident molecularly but not morphologically, implying that the relapse had arisen in a sanctuary CNS site. In the second patient, a first relapse in the marrow, which was induced into morphologic and molecular remission by chemotherapy and donor lymphocyte infusion, was followed by extramedullary relapses without any subsequent involvement of the marrow. This suggested that factors, likely to be due to a GVL effect, were stronger in the marrow than in peripheral tissues.
For adult acute lymphoblastic leukaemia (ALL), bone marrow transplantation (BMT) from an HLA-identical donor offers the best chance of cure. 1 This is attributed partly to high-dose chemotherapy and radiotherapy (RT), and partly to an immunological graft-versus-leukaemia (GVL) effect, tem (CNS) and testes, is common in ALL. 3 Extramedullary disease is rarely isolated, and almost always exists with, or heralds systemic marrow disease. 4 However, isolated extramedullary relapse after BMT in the absence of marrow involvement has occasionally been reported. The underlying mechanisms leading to selective sparing of the marrow in these cases remain undefined. We describe two patients with extramedullary relapse of ALL after allogeneic BMT from HLA-identical siblings. Despite recurrent extramedullary disease, both patients retained morphological remission and full donor chimerism in the marrow. The possible underlying mechanisms of isolated extramedullary relapses as revealed by investigations in these two cases are discussed.
Materials and methods

Case reports
Patient 1 was a 37-year-old woman presenting with Philadelphia (Ph) chromosome-positive common ALL. A short complete remission (CR) of 3 months was obtained with combination induction chemotherapy. 5 The disease relapsed in the bone marrow (BM) and CNS, and she underwent allogeneic BMT with the leukaemia not in remission from an HLA-identical brother donor. Etoposide (60 mg/kg), cyclophosphamide (CY) (100 mg/kg), and total body irradiation (TBI) (12 Gy) were used as conditioning, and cyclosporin A (CsA) alone as GVHD prophylaxis. She engrafted with grade II acute GVHD, and later extensive chronic GVHD affecting the lung and skin. One year after BMT she relapsed in the CNS. Bone marrow examination was normal. She was treated with intrathecal methotrexate (MTX) and cranial irradiation. Unfortunately, the marrow donor refused leukapheresis for DLI. Six months after relapse she died from refractory CNS leukaemia. The marrow had remained in remission until death.
Patient 2 was a 36-year-old woman presenting with T-ALL and involvement of the mediastinum and pleura. CR was obtained with combination induction chemotherapy. 5 An allogeneic BMT was performed with an HLA-identical sister as donor, using CY (120 mg/kg)/TBI (12 Gy) as conditioning, and CsA/MTX as GVHD prophylaxis. She engrafted with grade I acute GVHD and limited chronic GVHD. One year after BMT she relapsed in the BM and the CNS. A second CR was obtained with low-dose chemotherapy (MTX 300 mg ϫ 4 doses, vincristine 2 mg ϫ 4 doses) and intrathecal MTX (12 mg ϫ 7 doses). DNA fingerprinting post chemotherapy revealed reconstitution with donor marrow and DLI was given (total cell dose 7.2 ϫ 10 8 /kg). She developed extensive chronic GVHD, clinically affecting the lung, skin and liver, which was histologically confirmed in the skin. The patient was treated with azathioprine, steroid and CsA. No more chemotherapy was given. Her GVHD abated but did not totally subside. One year after DLI, a second relapse developed in an extramedullary site. She presented with obstructive jaundice and a computerised tomographic scan showed an 8 cm pancreatic mass, which on biopsy revealed infiltration by leukaemic cells. Several more retroperitoneal sites were repeatedly involved later. The donor refused a second peripheral blood lymphocyte harvest. Palliative chemotherapy and radiation were administered.
Fluorescence in situ hybridisation (FISH) and molecular studies
FISH analysis was performed on marrow smears with a chromosome X centromeric probe (Oncor, Gaithersburg, MD, USA) as previously described. 6 DNA fingerprinting was performed by Southern blotting with a 32 P-labelled M13 phage probe on HaeIII and HinfI digested donor and recipient DNA. 7 Reverse transcription polymerase chain reaction (RT-PCR) for the p190 fusion bcr/abl transcript characteristic of t(9;22) in ALL was performed with two pairs of nested bcr and abl primers, 8 with a sensitivity of 10 Ϫ5 to 10
Ϫ6
. Integrity of mRNA was shown by amplification of the ␤-2-microglobulin transcript. PCR for the T cell receptor (TCR) ␥ gene was performed with two pairs of V ␥ and J ␥ primers as previously described, 9 with a sensitivity of 10
Ϫ3
Results
Morphology, FISH and molecular analysis
The marrow morphology, FISH and molecular analysis results are shown in Table 1 . The marrow of both patients had remained in morphologic remission post BMT, defined as less than 5% blast cells. In patient 1, the marrow had remained in remission and was negative for bcr/abl after BMT (Figure 1a) . At the time of CNS relapse, although the marrow was in morphologic remission and FISH showed predominance of donor cells (Table 1) , bcr/abl became positive, indicating the presence of minimal leukaemic cells. Remarkably, despite persistent CNS leukaemia until death, the marrow had remained in morphologic remission, albeit with positive bcr/abl. In patient 2, PCR for TCR␥ gene was positive at the time of first relapse after BMT (Figure 1b) . However, the marrow achieved remission, became repopulated by donor cells as shown by DNA fingerprinting (data not shown), and PCR negative after chemotherapy and DLI. Subsequently, despite multiple episodes of extramedullary relapse, leukaemic infiltration did not occur in the marrow, which had remained in morphologic and molecular remission. The leukaemic cells in the pancreatic relapse were not available for molecular analysis.
Discussion
Isolated extramedullary relapses of leukaemia without concomitant involvement of the marrow are uncommon after allogeneic BMT. 6, 10 Selective involvement of extramedullary sites with sparing of the marrow might be due to a number of mechanisms. The extramedullary sites involved might represent 'sanctuary' sites for the conditioning chemo-radiotherapy. 3, 11 Alternatively, there might be a stronger GVL effect in the marrow than in peripheral tissues, which might be attributable to an absence of GVL effector cells in other bodily tissues, or the lack of a suitable milieu of cytokines or other molecules for the effector cells to function maximally. 12 The first patient would appear to concur with the former mechanism. After BMT, the marrow had remained in morphologic and molecular remission. At the time of CNS relapse and subsequently during refractory CNS leukaemia, the marrow was still in remission, although minimal leukaemia was demonstrable molecularly. This suggested that the CNS was the primary site of relapse, and the marrow was only secondarily involved. Therefore, the overall features were consistent with residual leukaemia at a sanctuary CNS site after BMT. Such a clinical course has been reported to be extremely uncommon after allogeneic bone marrow transplantation, 11 but relatively common in 'isolated' CNS relapse after chemotherapy in ALL. 13 On the other hand, our second case appeared to support the latter mechanism. After BMT, the marrow was the primary site of relapse. After administration of chemotherapy and DLI, the marrow was in morphologic and molecular remission. The subsequent occurrence of repeated episodes of extramedullary relapse did not lead to infiltration of the marrow by leukaemic cells, suggesting that there were factors, likely to be a GVL effect, that were preventing marrow relapse. Interestingly, the extramedullary sites involved, including the pancreas and the retroperitoneum, were also areas least affected by GVHD, suggesting that these might also be 'sanctuary sites' from the GVL effect. In fact, isolated extramedullary relapses of leukaemia with noninvolved marrow after allogeneic BMT have been consistently, albeit infrequently, reported. 6, 10, [14] [15] [16] These reports, together with the present case, would support a possible differential favourable effect of GVL on the marrow as compared with other peripheral sites.
These mechanisms are, of course, not mutually exclusive and may co-exist in patients. In the first case for instance, the marrow might be prevented from suffering a full blown relapse due to dissemination from the CNS by a stronger GVL effect. However, there may be practical significance in elucidating these mechanisms. Sanctuary sites might need to be tackled with additional therapy before BMT, such as CNS prophylaxis; 16 while the GVL effect might need to be augmented in high risk cases. 17 Finally, it is important to recognise that extramedullary relapses with non-involved marrow after BMT might be amenable to a combination of local treatment, systemic chemotherapy and therapy that aims at augmentation of GVL, 6, 10, 12, [14] [15] [16] and therefore consistent with prolonged survival.
